Epithelial cell transforming sequence 2 expression is associated with the progression of laryngeal squamous cell carcinoma

Abstract

Epithelial cell transforming sequence 2 (ECT2) is a guanine nucleotide exchange factor and its expression is associated with the development of malignant tumor types. However, to the best of our knowledge, there is no information on the role of ECT2 in the development and progression of laryngeal squamous cell carcinoma (LSCC). The present study aimed at investigating the expression pattern and potential role of ECT2 in the development and progression of LSCC. The expression of ECT2 in 81 pairs of LSCC and adjacent non-tumor tissues was characterized by immunohistochemistry and reverse transcription-quantitative polymerase chain reaction. ECT2 expression was upregulated in LSCC tissues and associated significantly with poor differentiation, higher stages, lymph node metastasis and poor survival in the sample population. The relative expression levels of ECT2 mRNA transcripts were correlated with the intensity of anti-ECT2 staining in 25 ECT2+LSCC specimens selected randomly. These results indicated that ECT2 expression was crucial for the progression of LSCC and may serve as a biomarker for the diagnosis and prognosis of LSCC.

ECT2 promotes the occurrence and is a prognostic biomarker of head and neck squamous cell carcinoma

“…The study by Sun et al found that ECT2 regulates the expression of VEGF and MMP9 through the RhoA-ERK signaling pathway in patients with esophageal squamous cell carcinoma 13 . Zhu et al explored the correlation between the high expression of ECT2 in laryngeal cancer and its association with low differentiation, advanced stage, lymph node metastasis, and poor survival rates 14 . Daizaburo Hirata et al discovered through immunohistochemical staining that high expression of ECT2 is associated with poor prognosis in patients with non-small cell lung cancer and esophageal squamous cell carcinoma 15 .…”